You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics at baseline in patients selected in the analysis and patients starting 3 or more cART in TAHOD

From: Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database

  In analysis In TAHOD   In analysis In TAHOD
Total patients 1676 4056 Haemoglobin (g/dL) at cART initiation
Age (year) at cART initiation    Median (IQR) 14.0 (12.6, 15.2) 12.3 (10.8, 14.2)
Median (IQR) 36 (30, 42) 35 (30, 41) < 10 g/dL 27 (2%) 418 (16%)
<=30 437 (26%) 1188 (29%) 10+g/dL 1248 (98%) 2250 (84%)
31~40 748 (45%) 1814 (45%) Not tested 221 1388
41 or more 491 (29%) 1054 (26%) CD4 count (cells/μL) at cART initiation
    Median (IQR) 140 (42, 230) 112 (37, 209)
Gender <=50 350 (28%) 990 (31%)
Male 1238 (74%) 2875 (71%) 51-100 155 (12%) 508 (16%)
Female 438 (26%) 1177 (29%) 101-200 328 (26%) 815 (26%)
Transgender 0 (0%) 4 (< 1%) 201-300 261 (21%) 551 (17%)
    301 or more 161 (13%) 311 (10%)
CDC clinical classification for HIV infection at cART initiation Not tested 421 881
Stage A 980 (58%) 1984 (50%) HIV viral load (copies/ml) at cART initiation
Stage B 101 (6%) 407 (10%) Median log10 (IQR) 4.93 (4.22, 5.52) 4.94 (4.32, 5.51)
Stage C 595 (36%) 1665 (41%) < 500 101 (11%) 126 (9%)
    501-10,000 80 (9%) 124 (9%)
Hepatitis B or C coinfection 10,001-50,000 173 (19%) 280 (20%)
No 1468 (88%) 3495 (86%) 50,001 or more 555 (61%) 885 (62%)
Yes 208 (12%) 566 (14%) Not tested 767 2641